SIGA Technologies, Inc. (NASDAQ:SIGA) Q4 2020 Earnings Conference Call March 4, 2021 4:30 PM ET Company Participants Phil Gomez - Chief Executive Officer Dennis Hruby - Chief Scientific Officer Dan Luckshire - Chief Financial Officer Conference Call Participants Max Jacobs - Edison Group Matthew Mark - Jet Capital Operator Greetings, and welcome to the SIGA Business Update call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2020 Or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ________ to ___________ Commission File No. 0-23047 SIGA Technologies, Inc. (Exact name of registrant as specified in its charter) incorporation ...

SIGA Technologies, Inc. (NASDAQ:SIGA) Q3 2020 Earnings Conference Call November 5, 2020 4:30 PM ET Company Participants Phillip Gomez - Chief Executive Officer Dan Luckshire - Chief Financial Officer Conference Call Participants Joaquin Horton - Raymond James Chris Thompson - Hutch Capital Matthew Mark - Jet Capital Operator Welcome to the SIGA Business Update Call. Before we turn the call over to SIGA management, please note that any forward-looking statements made during this call are based on management’ ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended September 30, 2020 Or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ________ to ___________ Commission File No. 0-23047 SIGA Technologies, Inc. (Exact name of registrant as specified in its charter) Delaw ...

SIGA Technologies, Inc. (NASDAQ:SIGA) Q2 2020 Earnings Conference Call August 6, 2020 4:30 PM ET Company Participants Phil Gomez – Chief Executive Officer Dan Luckshire – Chief Financial Officer Conference Call Participants Paul Saunders – Hedge Capital Joaquin Horton – Raymond James Teddy Green – Private Investor Andrew Sole – Esopus Creek Matthew Mark – Jet Capital Ralph Weil – R. Weil Investment Management Operator Greetings and welcome to the SIGA Technologies’ Second Quarter 2020 Financial Results Conf ...

WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended June 30, 2020 Or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ________ to ___________ Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Commission File No. 0-23047 SIGA Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 1 ...

SIGA Technologies, Inc. (NASDAQ:SIGA) Q1 2020 Earnings Conference Call May 6, 2020 4:30 AM ET Company Participants Phillip L. Gomez - CEO Daniel J. Luckshire - CFO Dennis E. Hruby - Chief Scientific Officer Conference Call Participants Joaquin Horton - Raymond James Paul Saunders - Hedge Capital Unidentified Analyst - Scott Sibley - Equis Group Operator Welcome to the SIGA business update call. At this time all participants are in a listen-only mode. A question-and-answer session will follow the formal pre ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended March 31, 2020 Or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ________ to ___________ Commission File No. 0-23047 SIGA Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware ...

Financial Data and Key Metrics Changes - SIGA's revenue for the year ended December 31, 2019, was approximately $27 million, consisting of about $11 million from the delivery of approximately 36,000 courses of oral TPOXX and approximately $16 million from research and development activities [17] - The company reported a pre-tax operating loss of approximately $2 million and a net loss per diluted share of $0.15 for 2019 [18] - As of December 31, 2019, SIGA had cash and cash equivalents of approximately $161 million, with about $96 million in restricted accounts available for loan-related payments [19] Business Line Data and Key Metrics Changes - The transition from the 1C BARDA contract to the 19C contract was highlighted, with substantial product deliveries and revenues expected to commence in 2020 [16] - The company anticipates delivering approximately 1.66 million courses of TPOXX to the Strategic National Stockpile (SNS) between 2020 and 2024, valued at approximately $532 million [14] Market Data and Key Metrics Changes - The international sales process for oral TPOXX is expected to be slow and unpredictable, with significant time required for government procurement [30][32] - SIGA is pursuing international sales, with a notable contract expected from the Canadian military for up to 15,825 courses of oral TPOXX [34] Company Strategy and Development Direction - The company has authorized a $50 million share repurchase program to signal confidence in its stock value and to create shareholder value [53] - SIGA is exploring new ways to expand its business beyond TPOXX, including collaborations for a second antiviral drug for smallpox treatment and potential acquisitions [54][56] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of preparedness in light of the COVID-19 outbreak and its potential impact on health security [10][12] - The company expects to deliver oral TPOXX courses valued at approximately $101 million to the SNS by April 2021, with deliveries starting in the second quarter of 2020 [21][57] Other Important Information - SIGA has received funding under the 19C contract for the development of a pediatric liquid formulation of TPOXX and for backup manufacturing capabilities [25][26] - The company is preparing a marketing authorization application for the European Medicines Agency (EMA) to expand TPOXX's indications [39] Q&A Session Summary Question: Was the language regarding the 19C contract shown to the customer before publication? - Management indicated that the projections come from the company and that they maintain close contact with customers but do not disclose specific approvals from BARDA [61] Question: How was the $50 million repurchase figure determined? - Management explained that the figure was chosen to signal that the share price is undervalued and to provide flexibility for future investments [64] Question: Concerns about the size of the repurchase relative to cash on hand? - Management acknowledged the concern and emphasized the importance of being disciplined in investment decisions while signaling confidence in the company's future [68]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2019 Or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ________ to ___________ Commission File No. 0-23047 SIGA Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 13-38 ...